• Read more about Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine Hydrochloride Injection Carpuject™ Units and Labetalol Hydrochloride Injection, USP Carpuject™ Units Due To The Potential For Incomplete Crimp Seals

FOR IMMEDIATE RELEASE – May 21, 2024 - NEW YORK, NY.,

Hospira, Inc., a Pfizer company (“Pfizer”), is voluntarily recalling the lots listed in the table below of Buprenorphine Hydrochloride Injection Carpuject^TM Units and Labetalol Hydrochloride Injection, USP Carpuject^TM Units to the User level. The recall was initiated due to the potential for incomplete crimp seals; one customer complaint has been received for one leaking unit.

• Read more about Pfizer Receives Positive CHMP Opinion for its Novel Antibiotic Combination for the Treatment of Patients with Multidrug-Resistant Infections and Limited Treatment Options

NEW YORK, March 22, 2024 – Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for EMBLAVEO® (aztreonam-avibactam) in the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.

• Read more about Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC®) protein degrader designed to target and degrade the estrogen receptor (ER) protein

• Read more about Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer

- Data from Phase 3 innovaTV 301 trial to be reviewed -

• Read more about Pfizer Receives Positive CHMP Opinion for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Candidate for Infants and Children

• 20vPnC offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine (PCV), helping to protect infants and children against all 20 serotypes contained in the vaccine
• Together, the 20 serotypes included in 20vPnC are responsible for the majority of currently circulating pneumococcal disease in the EU and globally ^{1,2,3,4,5,6,7,8} 
• The vaccine candidate builds on PREVENAR 13® and includes seven additional serotypes that are global causes of invasive pneumococcal disease (IPD) and are associated with high case-fa

• Read more about Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP ABBOJECT® Syringe; 8.4% Sodium Bicarbonate Injection, USP Lifeshield® ABBOJECT® Syringe; and Atropine Sulfate Injection, USP Lifeshield® ABBOJECT® Syringe

Recall due to the Potential For Presence of Glass Particulate Matter

FOR IMMEDIATE RELEASE - December 21, 2023 - NEW YORK, NY.

• Read more about Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Bleomycin for Injection, USP 15 Units Single Dose ONCO-TAIN™ Glass Fliptop Vial Due To The Potential For Presence of Glass Particulate Matter

FOR IMMEDIATE RELEASE - December 21, 2023 - NEW YORK, NY. 

Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Bleomycin for Injection, USP 15 units Single Dose ONCO-TAIN™ Glass Fliptop Vial, lot BL12206A, to the user level. The recall was initiated due to a confirmed customer report for the presence of glass particulate within a single vial. 

• Read more about Pfizer Receives Positive CHMP Opinion for Ulcerative Colitis Treatment

NEW YORK, December 15, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

• Read more about Pfizer’s TALZENNA® in Combination with XTANDI® Receives CHMP Positive Opinion in the European Union for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

Recommended indication is not specific to patient gene mutation status, including homologous recombination repair (HRR) gene mutations

• Read more about Pfizer’s PENBRAYA™ Receives Recommendation for Prevention of Meningococcal Disease in Adolescents and Young Adults from Advisory Committee on Immunization Practices

• PENBRAYA recommended for adolescents and young adults to help protect against the five leading causes of meningococcal disease
• PENBRAYA provides the broadest serogroup coverage (meningococcal group A, B, C, W, and Y) of any licensed meningococcal vaccine available in the U.S.

NEW YORK, October 25, 2023 — Pfizer Inc. (NYSE:PFE) announced today that the U.S.